No-Reflow Phenomenon Clinical Trial
Official title:
Evaluation of The Effect of Alpha Lipoic Acid Administration on Oxidative Stress Markers and Occurrence of No-Reflow Phenomenon in Post Myocardial Infarction Patients
Prospective, randomized, open-label, controlled clinical trial to evaluate the efficacy and tolerability of Alpha Lipoic Acid administration on oxidative stress, inflammatory markers, clinical outcome and occurrence of No-Reflow in post myocardial infarction (MI) patients by assessment of aldehyde dehydrogenase-2 (ALDH2) as a marker of oxidative stress and paraoxonase-1 (PON-1) as a marker of oxidative stress and inflammation.
All (60) STEMI patients undergoing PCI presenting to the Cardiology department will be randomly assigned into one of 2 arms: 30 patients undergoing PCI who will receive standard of care for 1 week, the other 30 patients undergoing PCI will receive standard of care in addition to Alpha Lipoic Acid 600 mg daily for 1 week. IV Alpha Lipoic Acid 600 mg once daily will be administered prior to PCI then orally daily for 1 week after PCI. Baseline evaluation included demographics and history taking. After obtaining the informed consent, information including age, weight, height, smoking state, and other diseases e.g. hypertension, diabetes, hyperlipidemias, etc. will be documented for each patient. Medication history in detail, as well as the background cardiovascular treatment, will be considered. All patients will be followed up regularly during the hospital stay and after discharge, will be assessed for the occurrence of adverse cardiac events and occurrence of adverse effects from medications ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03264859 -
NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction
|
N/A | |
Completed |
NCT04785209 -
Mean Platelet Volume and STEMI Clinical Risk Scores in Prediction of Impaired Myocardial Perfusion In Acute STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.
|
||
Not yet recruiting |
NCT06342141 -
Empagliflozin for No-reflow Phenomenon in PCI for STEMI
|
Phase 2 | |
Not yet recruiting |
NCT04835974 -
the No-reflow in Diabetic Patients Treated With Primary Percutaneous Coronary Intervention (PCI)
|
N/A | |
Completed |
NCT02054000 -
Intracoronary Tirofiban on No-Reflow Phenomena
|
Phase 4 | |
Not yet recruiting |
NCT05393557 -
Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction
|
N/A | |
Completed |
NCT04699110 -
Adrenaline for the Treatment of No-Reflow in Normotensive Patients
|
Phase 4 | |
Completed |
NCT04573751 -
The EPIVER Randomized Controlled Trial
|
N/A | |
Not yet recruiting |
NCT02233790 -
Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI
|
Phase 4 | |
Recruiting |
NCT05427786 -
A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT reductioN Of decREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT05355532 -
Genetic Determinants of the Coronary Microvascular Obstruction in PCI
|